Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Testosterone Undecanoate Patent Expiration

Testosterone Undecanoate is Used for treating conditions associated with deficiency or absence of endogenous testosterone in adult males, including primary hypogonadism and hypogonadotropic hypogonadism. It was first introduced by Endo Operations Ltd in its drug Aveed on Mar 5, 2014. Other drugs containing Testosterone Undecanoate are Kyzatrex, Jatenzo, Tlando. 4 different companies have introduced drugs containing Testosterone Undecanoate.


Testosterone Undecanoate Patents

Given below is the list of patents protecting Testosterone Undecanoate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Aveed US7718640 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels Mar 14, 2027 Endo Operations
Aveed US8338395 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels May 08, 2027 Endo Operations
Jatenzo US10543219 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr 12, 2030 Tolmar
Jatenzo US10617696 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr 12, 2030 Tolmar
Jatenzo US11179402 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same Apr 14, 2026 Tolmar
Jatenzo US11179403 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr 12, 2030 Tolmar
Jatenzo US11331325 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same Jan 06, 2027 Tolmar
Jatenzo US11426416 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr 12, 2030 Tolmar
Jatenzo US11564933 Methods of treating testosterone deficiency Apr 12, 2039 Tolmar
Jatenzo US8241664 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same Mar 29, 2029 Tolmar
Jatenzo US8492369 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Dec 20, 2030 Tolmar
Jatenzo US8778916 Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr 12, 2030 Tolmar
Kyzatrex US10576089 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols Dec 31, 2030 Marius Pharms Llc
Kyzatrex US10576090 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols Dec 31, 2030 Marius Pharms Llc
Kyzatrex US11590146 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols Dec 31, 2030 Marius Pharms Llc
Kyzatrex US11617758 Emulsion formulations Mar 15, 2033 Marius Pharms Llc
Tlando US10226473 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US10716794 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US11304960 Steroidal compositions Jan 08, 2029 Verity
Tlando US11311555 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US11364249 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US11433083 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US11464735 Fixed dose oral testosterone undecanoate compositions and use thereof Apr 28, 2041 Verity
Tlando US11559530 Oral testosterone undecanoate therapy Nov 28, 2037 Verity
Tlando US8778922 Steroidal compositions Jan 08, 2029 Verity
Tlando US8865695 Steroidal compositions Jan 08, 2029 Verity
Tlando US9943527 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity
Tlando US9949985 High-strength testosterone undecanoate compositions Nov 30, 2030 Verity


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Testosterone Undecanoate's patents.

Given below is the list recent legal activities going on the following patents of Testosterone Undecanoate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 09 Mar, 2023 US10226473
Surcharge for late Payment, Small Entity 09 Mar, 2023 US10226473
Recordation of Patent Grant Mailed 24 Jan, 2023 US11559530
Patent Issue Date Used in PTA Calculation 24 Jan, 2023 US11559530
Correspondence Address Change 09 Jan, 2023 US11464735
Email Notification 05 Jan, 2023 US11559530
Issue Notification Mailed 04 Jan, 2023 US11559530
Mail Miscellaneous Communication to Applicant 28 Dec, 2022 US11559530
Email Notification 28 Dec, 2022 US11559530
Miscellaneous Communication to Applicant - No Action Count 22 Dec, 2022 US11559530



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳